Completed PHASE4 INTERVENTIONAL NCT00304811

Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection

Vancomycin Versus Vancomycin Plus Gentamycin For Treating Bacteremic Infection Due to Methicillin-Resistant Staphylococcus Aureus (MRSA)

Sponsor: Baylor College of Medicine

Conditions Staphylococcus Aureus

Interventions Vancomycin Vancomycin plus Gentamicin Vancomycin plus Gentamicin plus Rifampin Vancomycin plus Rifampin

Updated 6 times since 2017 Last updated: Sep 25, 2009 Started: Jan 31, 2006 Primary completion: Jan 31, 2007 Completion: Jan 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00304811, this PHASE4 trial focuses on Staphylococcus Aureus and remains completed. Sponsored by Baylor College of Medicine, it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Nov 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Nov 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baylor College of Medicine
Michael E. DeBakey VA Medical Center

Data source: Michael E. DeBakey VA Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States